iPS Cells & Regenerative Medicine– category –
-
Stem Cell Therapies for Parkinson’s Disease Advance to Clinical Stages: BlueRock’s Phase 3 and Japanese iPSC Program Lead the Way
NeurologyLive USA Overview Stem cell therapies for Parkinson's Disease, particularly dopamine cell replacement trials, are making significant strides into advanced clinical stages. BlueRock Therapeutics' embryonic stem cell (ESC)-derived... -
BioCardia’s CardiAMP Autologous Cell Therapy Accelerates Towards Global Approval for Heart Failure
MerlinTrader (BioCardia分析) USA Overview BioCardia's CardiAMP autologous bone marrow cell therapy for cardiovascular disease has achieved significant regulatory milestones. The U.S. FDA confirmed that the ongoing Phase 3 CardiAMP Heart ... -
Intellia Therapeutics’ Lonvo-z Anticipates Key Phase 3 HAE Data Presentation at EAACI 2026
Simply Wall St USA Overview Intellia Therapeutics highlighted that additional data from the Phase 3 HAELO trial of lonvo-z (lonvoguran ziclumeran), its CRISPR-based therapy for hereditary angioedema (HAE), will be presented at the Europe... -
Beam Therapeutics’ Gene-Editing Candidate BEAM-302 Shows Positive Clinical Data in AATD Treatment, Hinting at Accelerated FDA Pathway
Simply Wall St USA Overview Beam Therapeutics reported positive clinical trial data for its gene-editing candidate, BEAM-302, demonstrating sustained protective protein levels in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Th... -
Century Therapeutics’ iPSC-Derived Type 1 Diabetes Therapy CNTY-813 Demonstrates Durable Glucose Control and Immune Evasion in Preclinical Studies
BioSpace (Century Therapeutics) USA Overview Century Therapeutics announced groundbreaking preclinical data for its iPSC-derived islet replacement therapy, CNTY-813, designed for Type 1 Diabetes (T1D) with Allo-Evasion™ 5.0 technology, a... -
Allogeneic BCMA CAR T Therapy CB-011 Achieves Deep Responses and Confirms Immune Cloaking in Multiple Myeloma Phase 1 Trial
The ASCO Post USA Overview CB-011, the first allogeneic anti-BCMA CAR T-cell therapy incorporating immune cloaking technology, achieved a high overall response rate (ORR) in its Phase 1 CaMMouflage trial for relapsed/refractory heavily p... -
Caribou Biosciences’ Off-the-Shelf Allogeneic CAR T Vispa-cel Shows Superior PFS to Approved Autologous CAR T Therapies in Lymphoma Phase 1
Fierce Biotech USA Overview Caribou Biosciences announced promising median progression-free survival (PFS) data from its Phase 1 clinical trial of vispacabtagene regedleucel (vispa-cel), an off-the-shelf allogeneic CAR T-cell therapy for... -
Imviva Biotech’s Off-the-Shelf Allogeneic CAR T Therapy CTD402 Achieves High Response Rates in Relapsed/Refractory T-ALL/LBL at EHA Presentation
GlobeNewswire (Imviva Biotech) USA Overview Imviva Biotech presented promising clinical data for its next-generation off-the-shelf allogeneic CAR T-cell therapy, CTD402, at the EHA 2026 annual meeting. The therapy targets adult and pedia... -
Fate Therapeutics Presents Positive Clinical and Preclinical Data for iPSC-Derived Off-the-Shelf CAR T Therapies FT819, FT839, and FT836 in Autoimmune Diseases and Solid Tumors
Fate Therapeutics USA Overview Fate Therapeutics unveiled updated clinical and preclinical data for its iPSC-derived off-the-shelf CAR T-cell programs at EULAR and in corporate presentations. The Phase 1 trial for anti-CD19 CAR T-cell th... -
Cellectis’ Lasme-cel Receives FDA RMAT Designation as First Allogeneic CAR T in Pivotal Trial for R/R B-ALL, EHA Data Confirms Efficacy
Stock Titan (Cellectis SEC Filing) USA Overview Cellectis announced that its CD22-targeting allogeneic CAR T-cell therapy candidate, lasme-cel (UCART22), has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA...
